Enoxaparin

Loading...
Thumbnail Image

Authors

Padayachee, N.
Schoeman, N.
Schellack, Natalie

Journal Title

Journal ISSN

Volume Title

Publisher

Medpharm Publications

Abstract

The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality.

Description

Keywords

Enoxaparin, Coagulopathy, Factor Xa, Low-molecular weight heparin (LMWH), COVID-19 pandemic, Coronavirus disease 2019 (COVID-19), Thrombotic conditions

Sustainable Development Goals

Citation

Padayachee N., Schoeman N. & Schellack, N. 2021, 'Enoxaparin', SA Pharmaceutical Journal, vol. 88, no. 2, pp. 26-29, doi : 10.10520/ejc-mp_sapj_v88_n2_a7.